Centessa Pharmaceuticals (NASDAQ:CNTA) Insider Mario Alberto Accardi Sells 8,000 Shares of Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) insider Mario Alberto Accardi sold 8,000 shares of the stock in a transaction on Monday, October 27th. The stock was sold at an average price of $25.00, for a total value of $200,000.00. Following the sale, the insider owned 194,394 shares of the company’s stock, valued at approximately $4,859,850. This represents a 3.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Mario Alberto Accardi also recently made the following trade(s):

• On Tuesday, September 16th, Mario Alberto Accardi sold 8,172 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $21.40, for a total value of $174,880.80.
• On Tuesday, September 9th, Mario Alberto Accardi sold 7,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $20.00, for a total value of $140,000.00.
• On Tuesday, July 29th, Mario Alberto Accardi sold 8,322 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.23, for a total value of $126,744.06.

Centessa Pharmaceuticals Stock Up 1.3%

Shares of Centessa Pharmaceuticals stock opened at $24.46 on Tuesday. The firm has a market cap of $3.28 billion, a price-to-earnings ratio of -13.66 and a beta of 1.57. The company has a debt-to-equity ratio of 0.32, a current ratio of 10.11 and a quick ratio of 10.12. Centessa Pharmaceuticals PLC Sponsored ADR has a 52-week low of $9.60 and a 52-week high of $25.30. The stock has a 50-day simple moving average of $21.09 and a 200-day simple moving average of $16.39.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.03). On average, equities research analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new stake in shares of Centessa Pharmaceuticals in the third quarter valued at about $572,000. China Universal Asset Management Co. Ltd. grew its position in shares of Centessa Pharmaceuticals by 4.8% in the second quarter. China Universal Asset Management Co. Ltd. now owns 19,181 shares of the company’s stock valued at $252,000 after purchasing an additional 870 shares during the last quarter. Exome Asset Management LLC grew its position in shares of Centessa Pharmaceuticals by 17.0% in the second quarter. Exome Asset Management LLC now owns 166,944 shares of the company’s stock valued at $2,194,000 after purchasing an additional 24,200 shares during the last quarter. Octagon Capital Advisors LP increased its holdings in shares of Centessa Pharmaceuticals by 24.8% during the 2nd quarter. Octagon Capital Advisors LP now owns 1,030,000 shares of the company’s stock worth $13,534,000 after purchasing an additional 205,000 shares during the period. Finally, BNP Paribas Financial Markets increased its holdings in shares of Centessa Pharmaceuticals by 3,028.1% during the 2nd quarter. BNP Paribas Financial Markets now owns 34,972 shares of the company’s stock worth $460,000 after purchasing an additional 33,854 shares during the period. 82.01% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CNTA has been the subject of a number of recent research reports. Wall Street Zen upgraded shares of Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday. Chardan Capital restated a “buy” rating and issued a $30.00 target price on shares of Centessa Pharmaceuticals in a report on Tuesday, August 12th. Oppenheimer began coverage on Centessa Pharmaceuticals in a report on Friday, August 29th. They set an “outperform” rating and a $40.00 price target on the stock. Truist Financial started coverage on shares of Centessa Pharmaceuticals in a research report on Monday, July 21st. They issued a “buy” rating and a $30.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $32.38.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.